Subha Vogeti

903 total citations
8 papers, 104 citations indexed

About

Subha Vogeti is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Subha Vogeti has authored 8 papers receiving a total of 104 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Oncology. Recurrent topics in Subha Vogeti's work include Musculoskeletal synovial abnormalities and treatments (3 papers), Cancer-related Molecular Pathways (3 papers) and Sarcoma Diagnosis and Treatment (2 papers). Subha Vogeti is often cited by papers focused on Musculoskeletal synovial abnormalities and treatments (3 papers), Cancer-related Molecular Pathways (3 papers) and Sarcoma Diagnosis and Treatment (2 papers). Subha Vogeti collaborates with scholars based in United States. Subha Vogeti's co-authors include Bryan D. Smith, Yu Mi Ahn, Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Cynthia B. Leary, Wei-Ping Lu, Scott Wise, Timothy M. Caldwell and Geeta Sharma and has published in prestigious journals such as Biochemistry, Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Subha Vogeti

8 papers receiving 98 citations

Peers

Subha Vogeti
Wei-Ping Lu China
Gilda De Paola Italy
Jiaoyu Ai China
Junhee Yoon United States
Charlotte O’Brien-Gore United Kingdom
Kristina Myhr‐Eriksson Sweden
Sarah Curry Ireland
Kenneth Grossman United States
Meike J. Saul Germany
Ana M. Diaz Espinosa United States
Wei-Ping Lu China
Subha Vogeti
Citations per year, relative to Subha Vogeti Subha Vogeti (= 1×) peers Wei-Ping Lu

Countries citing papers authored by Subha Vogeti

Since Specialization
Citations

This map shows the geographic impact of Subha Vogeti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Subha Vogeti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Subha Vogeti more than expected).

Fields of papers citing papers by Subha Vogeti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Subha Vogeti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Subha Vogeti. The network helps show where Subha Vogeti may publish in the future.

Co-authorship network of co-authors of Subha Vogeti

This figure shows the co-authorship network connecting the top 25 collaborators of Subha Vogeti. A scholar is included among the top collaborators of Subha Vogeti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Subha Vogeti. Subha Vogeti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Caldwell, Timothy M., Yu Mi Ahn, Stacie L. Bulfer, et al.. (2022). Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Bioorganic & Medicinal Chemistry Letters. 74. 128928–128928. 19 indexed citations
2.
Caldwell, Timothy M., Michael D. Kaufman, Scott Wise, et al.. (2022). Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 74. 128929–128929. 7 indexed citations
3.
4.
Smith, Bryan D., Michael D. Kaufman, Scott Wise, et al.. (2021). Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages. Molecular Cancer Therapeutics. 20(11). 2098–2109. 40 indexed citations
5.
Smith, Bryan D., Lakshminarayana Vogeti, Anu Gupta, et al.. (2019). Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers. Molecular Cancer Therapeutics. 18(12_Supplement). B129–B129. 6 indexed citations
6.
Nomanbhoy, Tyzoon, Geeta Sharma, Heidi E. Brown, et al.. (2016). Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response. Biochemistry. 55(38). 5434–5441. 26 indexed citations
7.
Smith, Bryan D., Michael D. Kaufman, Cynthia B. Leary, et al.. (2015). Abstract A53: The specific FMS kinase inhibitor, DCC-3014, durably inhibits FMS kinase in vivo and blocks cancer bone invasiveness. Cancer Research. 75(1_Supplement). A53–A53. 2 indexed citations
8.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wei-Ping Lu Breakdown of academic impact, for papers by Gilda De Paola Breakdown of academic impact, for papers by Jiaoyu Ai Breakdown of academic impact, for papers by Junhee Yoon Breakdown of academic impact, for papers by Charlotte O’Brien-Gore Breakdown of academic impact, for papers by Kristina Myhr‐Eriksson Breakdown of academic impact, for papers by Sarah Curry Breakdown of academic impact, for papers by Kenneth Grossman Breakdown of academic impact, for papers by Meike J. Saul Breakdown of academic impact, for papers by Ana M. Diaz Espinosa
Rankless by CCL
2026